Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferoxamine
Drug ID BADD_D00596
Description Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Indications and Usage Used to treat acute iron or aluminum toxicity (an excess of aluminum in the body) in certain patients. Also used in certain patients with anemia who must receive many blood transfusions.
Marketing Status approved; investigational
ATC Code V03AC01
DrugBank ID DB00746
KEGG ID D03670
MeSH ID D003676
PubChem ID 2973
TTD Drug ID D0FJ8A
NDC Product Code Not Available
UNII J06Y7MXW4D
Synonyms Deferoxamine | Desferrioxamine | Desferioximine | Deferoxamine B | Desferrioxamine B | Deferoximine | Deferrioxamine B | Desferroxamine | Desferrioxamine B Mesylate | Mesylate, Desferrioxamine B | Deferoxamine Mesilate | Mesilate, Deferoxamine | Deferoxamine Mesylate | Mesylate, Deferoxamine | Deferoxamine Methanesulfonate | Methanesulfonate, Deferoxamine | Desferal
Chemical Information
Molecular Formula C25H48N6O8
CAS Registry Number 70-51-9
SMILES CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory distress22.02.01.0120.001859%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001239%
Retinal degeneration06.09.03.002--Not Available
Retinal detachment12.01.04.004; 06.09.03.0030.001239%
Retinal disorder06.08.03.0050.001859%Not Available
Retinopathy06.10.02.001; 24.03.07.0030.003717%
Scab23.03.03.004--Not Available
Seizure17.12.03.0010.001859%
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.0060.001239%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.003346%Not Available
Splenomegaly01.09.02.0010.001859%Not Available
Swelling08.01.03.015--Not Available
Tachycardia02.03.02.0070.001859%Not Available
Therapeutic response decreased08.06.01.0160.001239%Not Available
Thrombocytopenia01.08.01.0020.001239%Not Available
Thrombocytosis01.08.02.0010.002726%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.001239%
Toxic encephalopathy17.13.01.004; 12.03.01.027--Not Available
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.0060.001239%
Unresponsive to stimuli17.02.05.0310.001239%Not Available
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria10.01.06.001; 23.04.02.001--
Vision blurred17.17.01.010; 06.02.06.0070.002478%
Visual acuity reduced06.02.10.012; 17.17.01.0110.008922%
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages